| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 12/27/2001 | US20010055571 Controlled unit dose to induce sedative-anxiolytic physiological response in the mammal, comprising lorazepam, nonaqueous, organic liquid solvent carrier and a preservative, in a manually actuated spray device |
| 12/27/2001 | US20010055569 Nasal drug delivery composition |
| 12/27/2001 | US20010055564 Intracellular pharmaceutical targeting |
| 12/27/2001 | CA2713965A1 Glycopeptide phosphonate derivatives |
| 12/27/2001 | CA2414064A1 Clear aqueous anaesthetic composition |
| 12/27/2001 | CA2413957A1 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 12/27/2001 | CA2413866A1 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 12/27/2001 | CA2413556A1 Positively-charged peptide nucleic acid analogs with improved properties |
| 12/27/2001 | CA2413253A1 Matrix protein compositions for dentin regeneration |
| 12/27/2001 | CA2412905A1 Improved injectable dispersions of propofol |
| 12/27/2001 | CA2412901A1 Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| 12/27/2001 | CA2412011A1 Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| 12/27/2001 | CA2411857A1 Peptides, compositions and methods for the treatment of burkholderia cepacia |
| 12/27/2001 | CA2411826A1 Liposomal encapsulation of chelated actinium-225 and uses thereof |
| 12/27/2001 | CA2410632A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | CA2410224A1 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
| 12/27/2001 | CA2410208A1 Systems and methods for treating a mucosal surface |
| 12/26/2001 | CN1328641A Nanoparticles with polymer shells |
| 12/26/2001 | CN1328473A Medicinal aerosol formulation |
| 12/26/2001 | CN1328467A Buffered composition for dialysis |
| 12/26/2001 | CN1328460A Pharmaceutical combination preparations |
| 12/26/2001 | CN1328459A Oral dosage formulations comprising (2S, 3S, 5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol and effective stabilizing amount of alginic acid |
| 12/26/2001 | CN1328454A Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| 12/26/2001 | CN1328450A Particles coated with granulated crystalline ibuprofen |
| 12/26/2001 | CN1328449A Application of water-soluble or water-dispersible polymerizates which contain poly-ether and which are used as coating agent, binding agent and/or as film-forming auxiliary agent in pharmaceutical for |
| 12/26/2001 | CN1328448A Fentanyl composition for treatment of acute pain |
| 12/26/2001 | CN1328447A Process for producing particles with converted amorphous and/or meta-stable crystalline region into crystalline state |
| 12/26/2001 | CN1328446A Improved fast disintegrating tablet |
| 12/26/2001 | CN1328445A Pressurised metered dose inhalers |
| 12/26/2001 | CN1328069A Process for preparing coating material as coating film of gastric disintegrable water medicine |
| 12/26/2001 | CN1327792A Method for controlling medicine dosage |
| 12/26/2001 | CN1076624C Nasally administrable compositions |
| 12/25/2001 | US6333410 Process for the preparation and purification of thiol-containing maytansinoids |
| 12/25/2001 | US6333361 Pharmaceutical composition containing zafirlukast |
| 12/25/2001 | US6333194 For delivering a virus vector to an animal tissue; gene therapy |
| 12/25/2001 | US6333054 Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties |
| 12/25/2001 | US6333051 Nanogel networks and biological agent compositions thereof |
| 12/25/2001 | US6333048 Solid medicament form with active agent distributed in flat polymer fragments |
| 12/25/2001 | US6333046 For physiologically active peptide to be absorbed more efficiently via a mucosa, especially a large intestine mucosa |
| 12/25/2001 | US6333045 Gatifloxacin or its salt and disodium EDTA to prevent coloration; eye, ear or nose drops |
| 12/25/2001 | US6333021 For delivery of therapeutically and/or diagnostically active substance, when in suspension in physiologically acceptable carrier useful as delivery vehicles for therapeutically active agents and/or as contrast agents for echographic imaging |
| 12/25/2001 | US6333020 Methods for treating AVM's using radio active compositions |
| 12/25/2001 | CA2208230C Controlled release formulation (albuterol) |
| 12/25/2001 | CA2029062C Biodegradable polymer compositions |
| 12/20/2001 | WO2001096590A2 Deesterified pectins, processes for producing such pectins, and stabilized acidic liquid systems comprising the same |
| 12/20/2001 | WO2001096528A2 Human tumor necrosis factor delta and epsilon |
| 12/20/2001 | WO2001096450A2 Fast cure film forming formulation |
| 12/20/2001 | WO2001096422A1 Process for the manufacture of hydrogel compositions and hydrogel compositions manufactured thereby |
| 12/20/2001 | WO2001096356A1 Antisense molecules and method of controlling expression of gene function by using the same |
| 12/20/2001 | WO2001095946A2 Combination product for carrying out a cytotoxic treatment in a mammal |
| 12/20/2001 | WO2001095945A2 Prodrug compounds cleavable by thimet oligopeptidase |
| 12/20/2001 | WO2001095944A2 Photocleavable prodrugs for selective drug delivery |
| 12/20/2001 | WO2001095943A2 Prodrug compounds with an oligopeptide having an isoleucine residue |
| 12/20/2001 | WO2001095942A2 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| 12/20/2001 | WO2001095941A1 Solid dispersions and medicines |
| 12/20/2001 | WO2001095939A1 Novel solid dispersion compositions |
| 12/20/2001 | WO2001095937A2 Phytoestrogenic isoflavone compositions |
| 12/20/2001 | WO2001095930A1 Method of photoreduction of hemoglobin vesicles |
| 12/20/2001 | WO2001095925A1 Pharmaceutical anti-inflammatory aerosol formulation |
| 12/20/2001 | WO2001095899A2 Pharmaceutical compositions comprising cannabidiol derivatives |
| 12/20/2001 | WO2001095894A2 Topical water-based anti-inflammatory compositions |
| 12/20/2001 | WO2001095886A1 Bioavailable dosage form of isotretinoin |
| 12/20/2001 | WO2001095885A1 Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrin antagonist |
| 12/20/2001 | WO2001095884A2 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 12/20/2001 | WO2001095883A1 Novel pharmaceutical formulation suitable for nebulisation |
| 12/20/2001 | WO2001095882A1 Novel aqueous anti-inflammatory pharmaceutical formulation |
| 12/20/2001 | WO2001095881A1 Pharmaceutical anti-inflammatory aerosol formulation |
| 12/20/2001 | WO2001095880A1 Novel pharmaceutical formulation suitable for nebulisation |
| 12/20/2001 | WO2001095879A1 Novel aqueous anti-inflammatory pharmaceutical formulation |
| 12/20/2001 | WO2001095878A1 Process for the preparation of a sterile ointment containing acyclovir |
| 12/20/2001 | WO2001095877A2 Porous celecoxib matrices and methods of manufacture thereof |
| 12/20/2001 | WO2001095875A1 Low molecular weight polymeric compositions |
| 12/20/2001 | WO2001095857A2 Reusable extracorporeal colums loaded with ligand-dibiotin conjugates |
| 12/20/2001 | WO2001070154A9 Device and method for treating urinary incontinence in females |
| 12/20/2001 | WO2001066550A3 Compounds for pdt |
| 12/20/2001 | WO2001064164A3 Nanocapsule encapsulation system and method |
| 12/20/2001 | WO2001062207A3 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| 12/20/2001 | WO2001054663A3 Surfactant free topical compositions and method for rapid preparation thereof |
| 12/20/2001 | WO2001052888A3 Improved dna vaccines for production-type animals |
| 12/20/2001 | WO2001052816A3 Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
| 12/20/2001 | WO2001051073A3 The parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| 12/20/2001 | WO2001050872A3 Method for produce sanitation using bacteriophages |
| 12/20/2001 | WO2001043545A3 Fluid insecticidal formulations for dermal treatment of parasitic insect larvae |
| 12/20/2001 | WO2001041911A3 Process for preparing ether-capped poly(oxyalkylated) alcohol surfactants |
| 12/20/2001 | WO2001039745A3 Aerosol composition comprising formoterol |
| 12/20/2001 | WO2001035937A3 Lipid complex of alkycyclines |
| 12/20/2001 | WO2001032230A3 A polymer micelle as monolayer or layer-laminated surface |
| 12/20/2001 | WO2001030391A3 Pharmaceutical composition containing midazolam |
| 12/20/2001 | WO2001022969A3 Vasopressin agonist formulation and process |
| 12/20/2001 | WO2001017566A3 L-selectin contrast agents |
| 12/20/2001 | WO2000024452A9 Systems and compounds for drug delivery to interstitial regions of the myocardium |
| 12/20/2001 | WO1997049394A3 Sold oral dosage forms of valsartan |
| 12/20/2001 | US20010053801 Inverse latexes based on white mineral oil, squalene or hydrogenated polyisobutene, cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions containing them |
| 12/20/2001 | US20010053791 Glycogen phosphorylase inhibitor |
| 12/20/2001 | US20010053778 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 12/20/2001 | US20010053548 Treating kidney tumors; administer human adjusted interferon, monitor tumor response to drugs |
| 12/20/2001 | US20010053388 Containing a bisphosphonate acid or its pharmaceutically acceptable salt dissolved in an aqueous solution, and a polymeric gel forming agent capable of inhibiting diffusion of the active ingredient with human tissue. |
| 12/20/2001 | US20010053385 Novel formulations comprising lipid-regulating agents |
| 12/20/2001 | US20010053373 Combining a solid dosage form and aqueous diluent in a single-use mixing and dosing cup having an abrasive interior surface and mixing to form a liquid dosage formulation. |
| 12/20/2001 | US20010053371 Molecule having an IL13-moiety and a cytotoxic moiety; especially for reducing growth of glioblastoma multiforme cells. |